Sodium Butyrate Stimulates PKC Activation and Induces Differential Expression of Certain PKC Isoforms during Erythroid Differentiation

Sodium butyrate (NaB) is an differentiation inducer currently under clinical investigation as a potential therapy for the treatment of sickle cell disease and prostate cancer. Though the biologic effects of this agent is well documented, its mechanism of action remains largely known. The mechanisms...

Full description

Saved in:
Bibliographic Details
Published inBiochemical and biophysical research communications Vol. 248; no. 3; pp. 664 - 668
Main Authors Rivero, Juan A., Adunyah, Samuel Evans
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 30.07.1998
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Sodium butyrate (NaB) is an differentiation inducer currently under clinical investigation as a potential therapy for the treatment of sickle cell disease and prostate cancer. Though the biologic effects of this agent is well documented, its mechanism of action remains largely known. The mechanisms by which it transduces its signal to the nucleus is the subject of intense investigation in our laboratory. In this report, we demonstrate that NaB stimulates PKC activation by 3-fold and induces differential expression of several PKC isoforms. Notably, it upregulates PKC epsilon and downregulates PKC beta during erythroid differentiation. These findings suggest that certain PKC isoforms may play important roles in the signal transduction mechanisms of this agent leading to regulation of erythroid proliferation and differentiation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0006-291X
1090-2104
DOI:10.1006/bbrc.1998.9041